The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
however if those suffering advanced covid had a medication that's only given to them, and it was shown early intervention could help .. that would be the use ...
the conclusion ...........
CONCLUDING REMARKS
Cellular stress and inflammation can activate or inhibit each other, depending on the immune cell type and the stress-inducing signals, such as pathogens and chemical or physical agents. Although understanding the pathophysiological role of cellular stress proteins in host defense and inflammatory diseases has progressed in recent years, future research should address critical questions. What are the key interacting mechanisms between stress-regulated cellular proteins and immune mediators crucial to host defense and disease pathogenesis? Can we target stress proteins to regulate inflammatory responses? An improved understanding of the underlying molecular mechanisms of stress proteins and their crosstalk with inflammatory pathways will provide new targets for therapeutic intervention.
the solution
Moditope
or further to WTP .. post
bit more of the technical reasons
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828604/
i was referring to your early posts that who else can "cross present" ... so i gave the link ref difficulty ..
hence i used .. "but it isn't " regarding the Title of the thread ....
now this Double activation .......... is the start of the process of vaccination ... not the End ........
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193623/
easy way to look at it is this ........ Scancell is a double vaccine ...
the Antibody its built around is also an "antigen presenting cell" but its a part timer ... which presents to other Professional Antigen presenting Cells .. and especially the one that has been transfected with the "plasmid" of DNA from immunobody
that plasmid is not an Antibody until the cell it transfected makes them using that instruction set
in effect its two vaccines in one .... the Plasmid and the Antibody
Burble your thoughts on that description ...
But It isn't ...
https://www.frontiersin.org/articles/10.3389/fimmu.2018.02874/full
inanaco
Posted in: SCLP
Posts: 32,864
Price: 14.85
No Opinion
RE: Deal21 Sep 2020 15:55
Back in the spring, at the Los Alamos National Laboratory in New Mexico, the computational biologist Bette Korber and her team were busy building the mathematical tools that would flag up such repeat offenders in the GISAID data.
“We didn’t expect to see anything so quickly,” she says. But already they had a candidate: “The D614G mutation stood out as such a case by early April.”
D614G refers to a switch in amino acid – from aspartate (D) to glycine (G) – at position 614 in the sequence of the protein that makes up the spikes of Sars-CoV-2. The spike is the protruding structure on the surface of the virus that binds to a human cell, allowing the virus to break in . After it has replicated inside the cell, its offspring break out again – killing the cell – and go on to infect others.
When Sars-CoV-2 emerged in Wuhan, it had a D at position 614. By June, G had replaced D almost everywhere in the world.
https://www.theguardian.com/world/2020/sep/18/mutant-virus-should-we-be-worried-sars-cov-2-changing-covid
well its 12 patient "dose escalation study" .. its not in anyway shape or form proof of efficacy .. that would require at least 30 patients which is why in the past Val talks about another trial to prove up that efficacy with a min cost of £5m i would suggest.
taken from Dec 2019 VAL 201 update
A late-stage study designed to determine the overall effectiveness of VAL201 and the most effective therapeutic strategies for its use in disease management, is now possible. This late-stage study will be designed and set up, in parallel to the conclusion of the current early-stage Phase I/IIa trial.
Hope it all goes well for you ...
my last post on the subject as we do need to move away from this
Dr John Chiplin, who is based in the US and is currently Scancell's Non-Executive Chairman, will assume the role of Executive Chairman. John will be directly involved in raising the corporate profile of the Company in the US. Recent US transaction experience, as a director/CEO, includes Benitec Biopharma (US IPO), Medistem (acquired by Intrexon), Arana (acquired by Cephalon) and Domantis (acquired by GSK). Prior to Scancell John was CEO of Polynoma, a Phase III cancer vaccine company, based in San Diego.
raising the Corporate Profile ...
success ...
Redmile
From Scib1 approved By the FDA to precede in the US
The Phase 2 study is designed to assess whether the addition of SCIB1 to pembrolizumab will result in an improvement in the tumour response rate, progression-free survival and overall survival in 25 patients with advanced melanoma, who are also eligible for treatment with pembrolizumab. Patient screening was initiated in the UK, with Professor Poulam Patel, Professor of Clinical Oncology at the University of Nottingham as the Chief Investigator for the global study.
US site initiation activities and patient enrolment will commence alongside clinical site expansion in the UK.
Dr Keith Flaherty, Professor of Medicine at Harvard Medical School and Director of Clinical Research at Massachusetts General Hospital Cancer Center, and clinical advisor to Scancell commented:
"Although checkpoint inhibitor combinations have improved outcomes for patients with melanoma, the toxicity of combinations such as ipilimumab plus nivolumab means that there remains a need to develop combinations with other investigational agents such as SCIB1, which have the potential to improve response rates without increasing toxicity."
Dr Cliff Holloway, Chief Executive Officer, Scancell, commented:
"We are delighted that our IND is now open, allowing us to progress our SCIB1 Phase 2 trial in the US as well as the UK. Approval will allow us to increase our overall patient recruitment rate and determine whether the addition of SCIB1 to current, standard of care treatment with pembrolizumab increases the anti-cancer response rate in patients with metastatic melanoma."
its clinical data from the US that will drive US policy ............ that FDA hold up running into Covid .... from the scientific side which stalled ...
while the commercial side bagged Redmile